Figure 1.
Prevalence and molecular spectrum of nonsynonymous somatic mutations discovered in plasma cfDNA. The percentage of training (A) and validation (D) DLBCL cases harboring nonsynonymous somatic mutations of genes investigated by targeted resequencing of plasma cfDNA. Color codes indicate the distribution of mutations among GC and non-GC DLBCL. The final number and prevalence of mutated cases is given for each gene. The molecular spectrum of nonsynonymous somatic mutations identified in plasma cfDNA of the training (B) and validation (E) DLBCL cases compared with the molecular spectrum of nonsynonymous somatic mutations that have been detected in the tumor gDNA of published DLBCL series and reported in the COSMIC database (version 76). Genes mutated in >10% cases of the DLBCL series are reported. The position and type of nonsynonymous somatic mutations that were identified in plasma cfDNA of the training (C) and validation (F) DLBCL cases. Genes mutated in >10% cases are reported. Mutation maps were obtained through MutationMapper version 1.0.1.